Document is current
Any future updates will be listed below
-
Authors
Agrawal, Saaket https://orcid.org/0000-0002-2535-4759
Wang, Minxian https://orcid.org/0000-0002-3753-508X
Klarqvist, Marcus D. R. https://orcid.org/0000-0001-7630-2708
Smith, Kirk
Shin, Joseph
Dashti, Hesam
Diamant, Nathaniel https://orcid.org/0000-0002-1738-304X
Choi, Seung Hoan https://orcid.org/0000-0002-2797-3190
Jurgens, Sean J. https://orcid.org/0000-0002-1605-9782
Ellinor, Patrick T.
Philippakis, Anthony
Claussnitzer, Melina
Ng, Kenney
Udler, Miriam S. https://orcid.org/0000-0003-3824-9162
Batra, Puneet https://orcid.org/0000-0001-6822-0593
Khera, Amit V. https://orcid.org/0000-0001-6535-5839
- License Information
-
More Information
Article History
Received: 8 December 2021
Accepted: 25 May 2022
First Online: 30 June 2022
Competing interests
: S.A. has served as a scientific consultant to Third Rock Ventures. M.D.R.K., A.P., and P.B. are supported by grants from Bayer AG applying machine learning in cardiovascular disease. P.T.E. receives sponsored research support from Bayer AG and IBM and has consulted for Bayer AG, Novartis, MyoKardia and Quest Diagnostics. A.P. is also employed as a Venture Partner at GV and consulted for Novartis; and has received funding from Intel, Verily and MSFT. M.C. holds equity in Waypoint Bio and is a member of the Nestle Scientific Advisory Board. K.N. is an employee of IBM Research. P.B. serves as a consultant for Novartis. A.V.K. is an employee and holds equity in Verve Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; and received a sponsored research agreement from IBM Research. The remaining authors declare no competing interests.
